

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/665,522	<u></u> •	09/22/2003	Andre Stamm	107664.115 US13	5813
26694	7590	07/28/2006		EXAMINER	
VENABLE	ELLP		SHEIKH, HUMERA N		
P.O. BOX 34385 WASHINGTON, DC 20045-9998				ART UNIT	PAPER NUMBER
				1615	
				DATE MAILED: 07/28/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	Office Action Summer:	10/665,522	STAMM ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Humera N. Sheikh	1615				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status			•				
1)[X]	Responsive to communication(s) filed on 19 Ju	ine 2006	•				
		action is non-final.					
	•—		secution as to the merits is				
<u>ا</u> رن	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
	closed in accordance with the practice under E	.x parte Quayre, 1000 O.D. 11, 40	0.0.270.				
Dispositi	on of Claims						
4)🛛	Claim(s) 1-39 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
-	5) Claim(s) is/are allowed.						
6)□	S) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)🖂	Claim(s) <u>1-39</u> are subject to restriction and/or e	election requirement.					
Applicati	on Papers						
9)[The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	ınder 35 U.S.C. § 119						
	Acknowledgment is made of a claim for foreign ☐ All b)☐ Some * c)☐ None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).				
	1. Certified copies of the priority document	s have been received.					
	2. Certified copies of the priority document	s have been received in Application	on No				
	3. Copies of the certified copies of the prior						
	application from the International Bureau	يا (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received. ** See the attached detailed Office action for a list of the certified copies not received. ** See the attached detailed Office action for a list of the certified copies not received. ** See the attached detailed Office action for a list of the certified copies not received. ** See the attached detailed Office action for a list of the certified copies not received. ** See the attached detailed Office action for a list of the certified copies not received. ** See the attached detailed Office action for a list of the certified copies not received. ** See the attached detailed Office action for a list of the certified copies not received. ** Paper No(s) (Mail Date Paper No(s)							
			HUMERA N. Cheller				
Attachmon	Nel		PATENT EXAMINERS				
Attachment	u(s) e of References Cited (PTO-892)	4) 🔲 Interview Summary	(BTO.413) TC-1600				
2) Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da					
3) 🔲 Inforr	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal P 6) Other:	atent Application (PTO-152)				
r ape		ол — опет					

Application/Control Number: 10/665,522

Art Unit: 1615

DETAILED ACTION

Status of the Application

Claims 1-39 are pending in this action. Claims 1-39 are subject to an Election/Restriction requirement.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-5, 8-12, 15-24 and 34-37, drawn to a fenofibrate composition with enhanced bioavailability (in the form of a tablet), classified in class 424, subclass 464.
- II. Claims 1-4, 6, 8-11, 13, 15, 25-35, 38 and 39, drawn to a fenofibrate composition with enhanced bioavailability (in the form of a capsule), classified in class 424, subclass 451.
- III. Claims 1-4, 7-11, 14, 15, 34 and 35, drawn to a fenofibrate composition with enhanced bioavailability (in the form of granulates), classified in class 424, subclass 489.

The inventions are distinct, each from the other because of the following reasons:

The claims of Group I (1-5, 8-12, 15-24 and 34-37) are drawn to a fenofibrate composition with enhanced bioavailability. The claims of Group I are in the form of a *tablet*. The claims of Group II (1-4, 6, 8-11, 13, 15, 25-35, 38 and 39) are drawn to a fenofibrate composition with enhanced

Application/Control Number: 10/665,522

Art Unit: 1615

bioavailability. The claims of Group II are in the form of a capsule. The claims of Group III (1-4, 7-11, 14, 15, 34 and 35) are drawn to a fenofibrate composition with enhanced bioavailability. The claims of Group III are in the form of granulates. Thus, Groups I, II and III are each drawn towards different pharmaceutical forms. The different inventions have different issues regarding patentability and enablement. Art anticipating Group I would not anticipate nor necessarily render obvious the claims of Groups II or III. Similarly, art anticipating Group II would not anticipate nor necessarily render obvious the claims of Groups I or III and so forth. The different inventions require completely different searches in both the patent and non-patent databases, and there is no expectation that the searches would be coextensive. This creates an undue search burden upon the Examiner. Furthermore, Groups I, II and III are capable of supporting a separate patent within the art, as also evidenced by their distinct classification.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143). Because the above restriction/election is complex, a telephone call to applicants to request an oral election was not made. See MPEP 812.01

Applicant is also reminded that a 1-month (not less than 30 days) shortened statutory period will be set for response when a written restriction is made without an action on the merits. This period may be extended under the provisions of 37 CFR 1.136(a).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Humera N. Sheikh whose telephone number is (571) 272-0604. The examiner can normally be reached on Monday through Friday from 8:00A.M. to 5:30P.M., alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Humera N. Sheikh Wunusan Sheille
Patent Examiner
TC-1600

Art Unit 1615

June 24, 2006

hns